Falsified Medicine Directive continued: Safety features on medicinal products and its consequences
GDPR and private sector life sciences
by Debbie Heywood and Sally Annereau
Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations
SPC manufacturing waiver (Part 2): The fairy tale of day-1 entry under the manufacturing and stockpiling waiver – a German view
Patenting of gene and protein sequences: an EU and US perspective
Taylor Wessing attracts second new international partner this month
First Dutch GDPR fine for failing to ensure security of patient files